Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure-Reference-Cited by-同舟云学术

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure

Published:2020-07-25 Issue:2 Volume:21 Page:205-217
ISSN:1175-3277
Container-title:American Journal of Cardiovascular Drugs
language:en
Short-container-title:Am J Cardiovasc Drugs

Author:

Alkhatib Nimer^ORCID,Sweitzer Nancy K.,Lee Christopher S.,Erstad Brian,Slack Marion,Gharaibeh Mahdi,Karnes Jason,Klimecki Walter,Ramos Kenneth,Abraham Ivo^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40256-020-00425-x.pdf

Reference22 articles.

1. The BEST Investigators. Beta-blocker evaluation of survival trial. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344(22):1659–67. https://doi.org/10.1056/NEJM200105313442202.

2. Tepper D. Frontiers in congestive heart failure: effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;5(4):184–5.

3. Domanski MJ, Krause-Steinrauf H, Massie BM, et al. A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS. J Card Fail. 2003;9(5):354–63. https://doi.org/10.1054/S1071-9164(03)00133-7.

4. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA. 2006;103(30):11288–93. https://doi.org/10.1073/pnas.0509937103.

5. Pereira NL, Weinshilboum RM. Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol. 2009;6(10):632–8. https://doi.org/10.1038/nrcardio.2009.154.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric cohorts and consortia can power and scale precision medicine;Comprehensive Precision Medicine;2024

2. Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review;Value in Health;2023-10

3. Genetically targeted bucindolol in NYHA III/IV HF not cost effective;PharmacoEconomics & Outcomes News;2020-08